Analysts play M&A chess with Actavis, Pfizer
This article was originally published in Scrip
Executive Summary
The $28bn acquisition of Forest Laboratories by Actavis just closed on 1 July, but Leerink Swann analyst Jason Gerberry already is speculating about the next strategic chess move for generic drug maker turned specialty pharmaceutical giant Actavis.